Abstract
Peripheral T-cell lymphomas (PTCLs) are an uncommon and heterogeneous group of well-differentiated, post-thymic T-cell malignancies that can present in the skin as cutaneous T-cell lymphomas. In general, their prognosis is poor, and specific therapy is not well defined. We report the successful treatment of a patient with relapsed, refractory PTCL who after failing 13 standard single and multiple chemotherapy regimens and experimental agents had a dramatic prolonged response to diftitoxin denileukin (ONTAK). This fusion protein, composed of diphtheria toxin coupled to interleukin-2, is approved for cutaneous T-cell lymphomas, including mycosis fungoides, and should be considered for treatment of the rare subset of peripheral T-cell lymphomas.
Publication types
-
Case Reports
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Aged
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / therapeutic use*
-
Diphtheria Toxin / administration & dosage
-
Diphtheria Toxin / therapeutic use*
-
Erythema / etiology
-
Humans
-
Interleukin-2 / administration & dosage
-
Interleukin-2 / therapeutic use*
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / pathology
-
Lymph Nodes / pathology
-
Lymphoma, T-Cell, Peripheral / drug therapy*
-
Lymphoma, T-Cell, Peripheral / pathology
-
Male
-
Nose Neoplasms / drug therapy
-
Nose Neoplasms / pathology
-
Receptors, Interleukin-2 / drug effects
-
Receptors, Interleukin-2 / metabolism
-
Recombinant Fusion Proteins / administration & dosage
-
Recombinant Fusion Proteins / therapeutic use*
-
Salvage Therapy
-
Skin Neoplasms / drug therapy
-
Skin Neoplasms / pathology
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Diphtheria Toxin
-
Interleukin-2
-
Receptors, Interleukin-2
-
Recombinant Fusion Proteins
-
denileukin diftitox